What is the recommended protocol for restarting clozapine after a nil per os (NPO) period?

Restarting Clozapine After NPO Period

When restarting clozapine after a nil per os (NPO) period, use the FDA-mandated re-titration protocol: resume at 40–50% of the established dose if one day was missed, approximately 25% if two days were missed, and restart at 12.5 mg once or twice daily for interruptions longer than two days. 1

Duration-Based Re-Titration Protocol

The FDA label provides explicit dosing thresholds based on the length of interruption 1:

• One day missed: Resume at 40–50% of the previous established dose 1
• Two days missed: Resume at approximately 25% of the previous established dose 1
• More than two days missed: Restart at 12.5 mg once or twice daily, then titrate upward more quickly than initial treatment if well-tolerated 1

Critical Safety Rationale

The dose reduction is mandatory to minimize the risk of orthostatic hypotension, bradycardia, and syncope—even brief interruptions require re-titration. 1 Case reports document delirium occurring when patients resumed their previous clozapine dose after interruptions as short as 2–10 days, underscoring that "even short breaks" necessitate cautious re-initiation. 2

Practical Titration After Longer Interruptions

When restarting at 12.5 mg after interruptions exceeding two days 1:

• Increase the total daily dose in increments of 25–50 mg per day if well-tolerated 1
• The dose may be increased to the previous therapeutic level more quickly than recommended for initial treatment (which targets 300–450 mg/day by the end of two weeks) 1
• Use divided dosing to further reduce orthostatic risk 1

Monitoring During Re-Initiation

Hematologic Monitoring

• Continue the existing ANC monitoring schedule that was in place before the interruption 1
• If the interruption was unrelated to neutropenia, monitor until ANC ≥1,500/μL (or ≥1,000/μL for benign ethnic neutropenia) 1
• If fever (≥38.5°C or 101.3°F) develops within two weeks after discontinuation, obtain additional ANC monitoring 1

Psychiatric and Cholinergic Monitoring

• Monitor carefully for recurrence of psychotic symptoms 1
• Watch for cholinergic rebound symptoms: profuse sweating, headache, nausea, vomiting, and diarrhea 1

Common Pitfalls to Avoid

Do not resume clozapine at the previous full dose after any interruption—this is the most dangerous error. Even a single missed day mandates dose reduction. 1, 2 The case literature shows that resuming at the prior tolerated dose after brief interruptions (2–10 days) can precipitate delirium. 2

Do not assume that a short NPO period (e.g., for surgery or procedures) is exempt from re-titration rules. The FDA protocol applies to "even a brief interruption," and the physiologic reset of cardiovascular tolerance occurs rapidly. 1

Special Considerations for NPO Contexts

In perioperative or acute medical settings where NPO status is temporary:

• Plan ahead: if the NPO period will exceed one day, anticipate the need for dose reduction upon resumption 1
• Coordinate with anesthesia and surgical teams to minimize the duration of clozapine interruption when feasible 1
• If the patient was on a stable therapeutic dose (e.g., 400 mg/day) and NPO for three days, restart at 12.5 mg once or twice daily, then escalate by 25–50 mg/day as tolerated—this may allow return to therapeutic dosing within one to two weeks rather than the standard two-week initial titration 1

Therapeutic Drug Monitoring After Re-Initiation

Once the patient returns to a stable maintenance dose:

• Measure trough clozapine levels (12 hours post-dose, before the morning dose) on at least two occasions one week apart 3, 4
• Target trough level ≥350 ng/mL for therapeutic efficacy 3, 4
• Levels between 350–550 ng/mL optimize efficacy while limiting seizure risk 4